Search

Search Results

• THE IMPACT OF THE SARS-CoV-2 PANDEMIC ON HEALTHCARE PROVISION IN ITALY TO NON-COVID PATIENTS: A SYSTEMATIC REVIEW

  Annarita Botta, Gianmarco Lugli, Matteo Maria Ottaviani, Guido Ascione, Alessandro Bruschi, Federico Cagnazzo, Lorenzo Zammarchi, Paola Romagnani, tommaso portaluri

  e2022012

  2022-01-01

  https://doi.org/10.4084/MJHID.2022.012

  2128

  PDF: 3703

  HTML: 1371

• Dose reduction of ibrutinib in chronic lymphocytic leukemia: long-term outcomes from a real-world single-center experience

  Roberta Laureana

  e2026090

  2026-10-31

  https://doi.org/10.4084/MJHID.2026.090

  110

  PDF: 56

  Html: 16

• First-Line Flumatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A 3-Month Landmark-Evaluable Real-World Experience

  Dangui Chen

  e2026066

  2026-09-01

  https://doi.org/10.4084/MJHID.2026.066

  178

  PDF: 98

  Html: 61

• TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE

  Maël Heiblig, Mohamed Elhamri, Isabelle Tigaud, Adriana Plesa, Fiorenza Barraco, Hélène Labussière, Sophie Ducastelle, Mauricette Michallet, Franck Nicolini, Claudiu Plesa, Eric Wattel, Gilles Salles, Xavier Thomas

  e2016009

  2016-01-01

  https://doi.org/10.4084/mjhid.2016.009

  7827

  PDF: 1639

  HTML: 1670

• OUTCOME OF FRONTLINE TREATMENT WITH “GENERIC” IMATINIB IN ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN ALGERIAN POPULATION: A MULTICENTER STUDY

  Mohamed Amine BEKADJA

  e2017062

  2017-10-25

  https://doi.org/10.4084/mjhid.2017.062

  3078

  PDF: 823

  HTML: 952

• Ruxolitinib-Treated Myeloproliferative Neoplasms: Real-World Infectious Outcomes and Preventive Practices from a Single Center

  Muruvvet Seda Aydin, Gulten Korkmaz, Merve Pamukcuoglu, Hatice Rahmet Guner, Funda Ceran, Simten Dagdas, Gulsum Ozet

  e2026044

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.044

  408

  PDF: 437

  HTML: 88

• AUTOLOGOUS STEM CELL TRANSPLANTATION IN ELDERLY ACUTE MYELOID LEUKEMIA

  Gert J. Ossenkoppele, Jeroen J.W.M. Janssen, Peter C. Huijgens

  e2013018

  2013-02-16

  https://doi.org/10.4084/mjhid.2013.018

  2656

  PDF: 928

  HTML: 3300

• EPIDEMIOLOGY, DIAGNOSIS AND TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN CHILDREN: THE EXPERIENCE IN CHINA

  Li Zhang, Xiaofan Zhu

  e2012012

  2012-03-10

  https://doi.org/10.4084/mjhid.2012.012

  2553

  PDF: 944

  HTML: 2326

  New table Chinese children with APL: 222

• PATHOBIOLOGY OF HODGKIN LYMPHOMA

  Claudio Agostinelli, Stefano Pileri

  e2014040

  2014-06-05

  https://doi.org/10.4084/mjhid.2014.040

  3766

  PDF: 1809

  HTML: 5991

  Fig1-Ag-Pil: 297

  Ag-Pil Fig.2: 293

• TREATMENT OF NEWLY DIAGNOSED POEMS SYNDROME: BORTEZOMIB OR LENALIDOMIDE? EXPERIENCE FROM TWO COUNTRIES

  Deniz Ozmen, Francesco Autore, Tuba Ozkan, Gunel Musayeva, Zeliha Birsin, Daniele Mannina, Federica Lessi, Daniele Derudas, Umut Yilmaz, Tugrul Elverdi, Ahmet Emre Eskazan, Muhlis Cem Ar, Zafer Baslar, Stefania Bramanti, Luca Laurenti, Ayse Salihoglu

  e2026084

  2026-10-31

  https://doi.org/10.4084/MJHID.2026.084

  124

  PDF: 65

  Suppl. Files: 20

  Html: 25

  Html Suppl. Files: 27

• OPTIMIZATION OF THE CLINICAL JOURNEY OF UNFIT PATIENTS WITH NEWLY DIAGNOSED IDH1M ACUTE MYELOID LEUKEMIA

  Adriano Venditti, Marta Riva, Livio Pagano, Giovanni Marconi, Nicola Fracchiolla, Romano Danesi, Antonio Curti, Anna Candoni, Erika Borlenghi, Maria Teresa Voso

  e2026086

  2026-10-31

  https://doi.org/10.4084/MJHID.2026.086

  138

  PDF: 82

  Html: 25

• UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)

  José Luis Piñana, Estela Giménez, Lourdes Vázquez, María Ángeles Marcos, Manuel Guerreiro, Rafael Duarte, Ariadna Pérez, Carlos de Miguel, Ildefonso Espigado, Marta González-Vicent, María Suarez-Lledó, Irene García-Cadenas, Rodrigo Martino, Angel Cedillo, Monserrat Rovira, Rafael de la Cámara, David Navarro, Carlos Solano

  e2024065

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.065

  4757

  Suppl. Files: 1293

  PDF: 1194

  Html: 345

• NATION-WIDE SURVEY ON THE USE OF THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RA) FOR THE MANAGEMENT OF IMMUNE THROMBOCYTOPENIA IN CURRENT CLINICAL PRACTICE IN ITALY

  Francesco Rodeghiero, Dr. Mariasanta Napolitano, Nicola Vianelli, Lisanna Ghiotto, Silvia Cantoni, Giuseppe Carli, Monica Carpenedo, Valentina Carrai, Ugo Consoli, Gaetano Giuffrida, Elisa Lucchini, Elena Rossi, Cristina Santoro

  e2023019

  2023-02-28

  https://doi.org/10.4084/MJHID.2023.019

  2602

  PDF: 1373

  PDF Appendix: 840

  HTML: 571

• THE GROWING ROLE OF THE BH3 MIMETIC DRUG VENETOCLAX IN THE THERAPY OF ACUTE MYELOID LEUKEMIA

  Elvira Pelosi, Dr. Germana Castelli, Ugo Testa

  e2022080

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.080

  1753

  PDF: 1318

  HTML: 661

• PEDIATRIC HODGKIN LYMPHOMA IN LOW- and MIDDLE-INCOME COUNTRIES (LMICs). A NARRATIVE REVIEW Pediatric Hodgkin's lymphoma in low-income countries

  Dr, Moleti, Anna Maria Testi

  e2024078

  2024-10-31

  https://doi.org/10.4084/MJHID.2024.078

  1455

  PDF: 1003

  HTML: 372

• ACUTE PROMYELOCYTIC LEUKEMIA: AN EXPERIENCE ON 95 GREEK PATIENTS TREATED IN THE ALL-TRANS-RETINOIC ACID ERA

  Maria Pagoni, Maria Garofalaki, Fotios Panitsas, Kalliopi Manola, Katerina Psarra, Panagiotis Economopoulos

  e2011053

  2011-11-28

  https://doi.org/10.4084/mjhid.2011.053

  3035

  PDF: 995

  HTML: 3644

• ACUTE PROMYELOCYTIC LEUKEMIA (APL): COMPARISON BETWEEN CHILDREN AND ADULTS

  Anna Maria Testi, Francesco Lococo

  e2014032

  2014-04-15

  https://doi.org/10.4084/mjhid.2014.032

  3104

  PDF: 1805

  HTML: 2392

• PREVENTION OF ? THALASSEMIA IN NORTHERN ISRAEL - A COST-BENEFIT ANALYSIS.

  Ariel Koren, Lora Profeta, Luci Zalman, Haya Palmor, Carina Levin, Ronit Bril Zamir, Stavit Shalev, Orna Blondheim

  e2014012

  2014-02-17

  https://doi.org/10.4084/mjhid.2014.012

  3395

  PDF: 1486

  HTML: 11881

• Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA

  Michele Puppi, Ilaria Sacchetti, Katia Mancuso, Paola Tacchetti, Lucia Pantani, ilaria Rizzello, Miriam Iezza, Marco Talarico, Enrica Manzato, Simone Masci, Roberta Restuccia, Simona Barbato, Silvia Armuzzi, Barbara Taurisano, Ilaria Vigliotta, Elena Zamagni

  e2025045

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.045

  1914

  PDF: 1456

  HTML: 688

• BACTERIAL BLOOD STREAM INFECTIONS NEGATIVELY IMPACT ON OUTCOME OF PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION: 6 YEARS SINGLE-CENTRE EXPERIENCE

  Michele Malagola

  e2017036

  2017-06-20

  https://doi.org/10.4084/mjhid.2017.036

  4977

  PDF: 952

  HTML: 1128

• OUTCOME AND TOXICITY PATTERNS IN CHILDREN AND ADOLESCENTS WITH NON-HODGKIN LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE

  Paola Angelini, Laura Rodriguez, Mohammed Zolaly, Ahmed Naqvi, Sheila Weitzman, oussama Abla, Angela Punnett

  e2018020

  2018-03-01

  https://doi.org/10.4084/mjhid.2018.020

  3118

  PDF: 940

  HTML: 442

• INFECTIONS IN MYELODYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY

  Giuseppe Leone, Livio Pagano

  e2018039

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.039

  4526

  PDF: 1560

  HTML: 818

• AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA: AN EFFECTIVE AND MANAGEABLE APPROACH.

  Pasquale Niscola

  e2014020

  2014-02-16

  https://doi.org/10.4084/mjhid.2014.020

  3194

  PDF: 986

  HTML: 2812

• ANTIFUNGAL THERAPY IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS

  Alessandro Busca, Livio Pagano

  e2016039

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.039

  5023

  PDF: 1651

  HTML: 2291

  Untitled: 288

  Untitled: 309

  Untitled: 330

  Untitled: 284

  Untitled: 294

• EVOLUTION OF HEMOGLOBINOPATHY PREVENTION IN AFRICA

  Slaheddine Fattoum

  e2009005

  2009-10-27

  1165

  PDF: 476

  HTML: 15088

• IMPACT OF MULTIPLEX PCR IN REDUCING THE RISK OF RESIDUAL TRANSFUSION-TRANSMITTED HUMAN IMMUNODEFICIENCY AND HEPATITIS B AND C VIRUSES IN BURKINA FASO

  Arzouma Paul YOODA, Serge Theophile SOUBEIGA, Kompingnin Yacouba NEBIE, Birama DIARRA, Salam SAWADOGO, Abdoul Karim OUATTARA, Dorcas OBIRI-YEBOAH, Albert Theophane YONLI, Issoufou TAO, Pegdwende Abel SORGHO, Honorine DAHOUROU, Jacques SIMPORE

  e2018041

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.041

  2667

  PDF: 1077

  HTML: 374

• THROMBOTIC MICROANGIOPATHY IN HAEMATOPOIETIC CELL TRANSPLANTATION:AN UPDATE

  Evi Stavrou, Hillard Michael Lazarus

  e2010033

  2010-10-29

  https://doi.org/10.4084/mjhid.2010.033

  1789

  PDF: 1164

  HTML: 10923

• A MULTICENTER EXPERIENCE FROM LEBANON IN CHILDHOOD AND ADOLESCENT ACUTE MYELOID LEUKEMIA:HIGH RATE OF EARLY DEATH IN CHILDHOOD ACUTE PROMYELOCYTIC LEUKEMIA.

  Roula Antoine Farah

  e2015012

  2014-12-27

  https://doi.org/10.4084/mjhid.2015.012

  3586

  PDF: 1215

  HTML: 7767

  cover letter paper final AML: 286

• Guest Editor: Pellegrino Musto AN UPDATE OF THE APPROPRIATE SEQUENCING FOR SALVAGE THERAPIES IN MULTIPLE MYELOMA

  Gregorio Barila', Francesca Rezzonico, Laura Pavan, Alessandro Corso, Renato Zambello

  e2025043

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.043

  1316

  PDF: 1054

  HTML: 529

• the EARLY TREATMENT WITH BAMLANIVIMAB ALONE DOES NOT PREVENT COVID-19 HOSPITALIZATION AND ITS POST-ACUTE SEQUELAE. A REAL EXPERIENCE IN UMBRIA, ITALY.

  Elisabetta Schiaroli, Giuseppe Vittorio De Socio, Laura Martinelli Martinelli, lisa malincarne, Martina Savoia, Anna Laura Spinelli, Daniela Francisci

  e2021061

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.061

  2132

  PDF: 509

  HTML: 259

• PROGNOSTIC IMPACT OF WT-1 GENE EXPRESSION IN EGYPTIAN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA

  Adel Abd Elhaleim Hagag

  e2016008

  2016-01-01

  https://doi.org/10.4084/mjhid.2016.008

  4285

  PDF: 934

  HTML: 2516

• ALLOGENEIC TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA IN THE ERA OF NOVEL THERAPIES: CHANGING INDICATIONS AND DYNAMIC RISK ASSESSMENT

  Simona Sica, Filippo Frioni, Matteo Breccia, Patrizia Chiusolo

  e2026088

  2026-10-31

  https://doi.org/10.4084/MJHID.2026.088

  109

  PDF: 89

  Html: 47

• CURRENT STRATEGIES FOR THE DETECTION OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA

  Juliana Maria Camargos Rocha, Sandra Guerra Xavier, Marcelo Eduardo Lima Souza, Juliana Godoy Assumpção, Mitiko Murao, Benigna Maria Oliveira

  e2016024

  2016-04-10

  https://doi.org/10.4084/mjhid.2016.024

  4886

  PDF: 1438

  HTML: 4989

• THE CHALLENGE OF AML IN OLDER PATIENTS

  Alan K Burnett

  e2013038

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.038

  2514

  PDF: 1097

  HTML: 2250

• GOOD OUTCOME FOR VERY HIGH RISK ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA CARRYING GENETIC ABNORMALITIES t(4;11)(q21;q23) or t(9;22)(q34;q11), IF PROMPTLY SUBMITTED TO ALLOGENEIC TRANSPLANTATION, AFTER OBTAINING A GOOD MOLECULAR REMISSION.

  Matteo Parma, Clara Vigano', Monica Fumagalli, Federica Colnaghi, Arianna Colombo, Federica Mottadelli, Vincenzo Rossi, Elena Elli, Elisabetta Terruzzi, Angelo Belotti, Giovanni Cazzaniga, Enrico Maria Pogliani, Pietro Pioltelli

  e2015041

  2015-05-26

  https://doi.org/10.4084/mjhid.2015.041

  2346

  PDF: 1119

  HTML: 1252

• CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL

  Ugo Testa, Prof. Sica, Dr. Pelosi, Dr. Germana Castelli, Prof. Leone

  e2024010

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.010

  4846

  PDF: 3982

  HTML: 384

• PLASMA CELL LEUKEMIA UPDATE ON IMMUNOPHENOTYPE, MOLECULAR CHARACTERISTICS, AND THERAPY. The second part of plasma cell neoplasms with spreading in the blood and tissues Plasma Cell Leukemia

  Giuseppe G.M. Leone, Ugo Testa

  e2025080

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.080

  1813

  PDF: 463

  Html: 293

• MOLECULAR MARKERS IN AML: PROGNOSTIC IMPLICATIONS AND IMPACT ON TREATMENT DECISION-MAKING

  Patrizia Chiusolo, Roberto Maggi, Angela Alessi, Simona Sica

  e2026087

  2026-10-31

  https://doi.org/10.4084/MJHID.2026.087

  127

  PDF: 79

  Html: 47

• TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS

  Luca Maurillo, Francesco Buccisano, Maria Ilaria Del Principe, Chiara Sarlo, Luigi Di Caprio, Concetta Ditto, Federica Giannotti, Daniela Nasso, Eleonora Ceresoli, Massimiliano Postorino, Marco Refrigeri, Sergio Amadori, Adriano Venditti

  e2013032

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.032

  3134

  PDF: 1124

  HTML: 5682

• TUBERCULOSIS IN HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS.

  Silvia F Costa, Jessica Ramos, Marjorie Vieira Batista

  e2013061

  2013-11-04

  https://doi.org/10.4084/mjhid.2013.061

  2891

  PDF: 1066

  HTML: 3771

• PRENATAL DIAGNOSIS OF ?-THALASSEMIAS AND HEMOGLOBINOPATHIES

  Maria Cristina Rosatelli, Luisella Saba

  e2009011

  2009-11-15

  2003

  PDF: 432

  HTML: 6543

• TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin

  Cristina Papayannidis, Vincenzo Federico, Luana Fianchi, Patrizia Pregno, Novella Pugliese, Alessandra Romano, Federica Irene Grifoni

  e2022073

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.073

  1491

  PDF: 1151

  HTML: 493

• EFFICACY AND SAFETY OF THALIDOMIDE IN PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA: A SYSTEMATIC REVIEW, META-ANALYSIS AND GRADE EVALUATION

  Jialian Li, Ping Ji, Qinyue Zhong, Lin Dong, Hai Yi, Baiyu Chen, Xu Zhang, Tingting Duan

  e2026033

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.033

  474

  PDF: 423

  Suppl. Files: 111

  HTML: 136

• CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.

  Vincenzo De Sanctis

  e2020006

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.006

  4504

  PDF: 1634

  HTML: 497

• A MULTICENTRE ICET-A STUDY OF CONFIRMED SARS-COV-2 INFECTION IN PATIENTS WITH HEMOGLOBINOPATHIES: PRELIMINARY DATA FROM 10 COUNTRIES

  Vincenzo De Sanctis

  e2020046

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.046

  3194

  PDF: 1689

  HTML: 383

• PHYSICIAN’S ATTITUDE TOWARDS TREATMENT OF OLDER PATIENTS AND THE CHOICE OF THERAPY

  Felicetto Ferrara

  e2013025

  2013-04-10

  https://doi.org/10.4084/mjhid.2013.025

  2545

  PDF: 886

  HTML: 2007

• EVOLVİNG PARADİGMS İN THE MANAGEMENT OF PRİMARY IMMUNE THROMBOCYTOPENİA İN ADULTS: FROM CORTİCOSTEROİDS TO TARGETED BİOLOGİC THERAPİES

  Massimo Martino, Laura Giordano, Maria Bruna Greve, Violetta Marafioti, Caterina Alati

  e2026067

  2026-09-01

  https://doi.org/10.4084/MJHID.2026.067

  404

  PDF: 380

  Html: 84

• RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CHEMOIMMUNOTHERAPY, TREATMENT UNTIL PROGRESSION WITH MECHANISM-DRIVEN AGENTS OR FINITE-DURATION THERAPY?

  Antonio Cuneo, Robin Foà

  e2019024

  2019-02-27

  https://doi.org/10.4084/mjhid.2019.024

  2921

  PDF: 1784

  HTML: 409

• THE PERFORMANCE OF HOMA 2 COMPARED TO DYNAMIC MARKERS OF INSULIN SECRETION AND SENSITIVITY/RESISTANCE FOR PREDICTING DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β-THALASSEMIA: THE EXPERIENCE OF A SINGLE CENTRE HOMA 2 and DYNAMIC MARKERS OF INSULIN SECRETION FOR PREDICTING DYSGLYCEMIA  in TDT

  Vincenzo De Sanctis, Shahina Daar, Ploutarchos Tzoulis, Ashraf Soliman, Ihab Elhakim , Mohammad Faranoush, Christos Kattamis

  e2026055

  2026-06-30

  https://doi.org/10.4084/MJHID.2026.056

  309

  PDF: 324

  HTML: 66

• ACUTE MYELOİD LEUKEMİA, MYELODYSPLASİA-RELATED: BEYOND CLASSİFİCATİON—TOWARD PRECİSİON DECİSİON-MAKİNG

  G Leone, U Testa, E Attardi, MT Voso

  e2026075

  2026-09-01

  https://doi.org/10.4084/MJHID.2026.075

  344

  PDF: 261

  Html: 168